DEFINITION
Cost–benefit analysis (CBA) is an economic assessment technique that compares the expected benefits of a project, merger, or regulatory intervention with its associated costs to determine its net impact on welfare.
In competition law, it is used to evaluate whether efficiency gains, innovation benefits, or consumer advantages outweigh anticompetitive effects such as price increases, output restriction, foreclosure, or loss of dynamic competition.1
Let us elaborate through an example. Suppose the government is considering building a new metro line in Delhi. The project may require significant expenditure on construction, land acquisition, and maintenance, amounting to around ₹20,000 crore. However, the metro line could yield several benefits, including reduced travel time for commuters, lower traffic congestion, decreased air pollution, and increased economic activity in surrounding areas. If these benefits are estimated to be worth ₹30,000 crore over time, the benefits exceed the costs by ₹10,000 crore. In such a case, a cost–benefit analysis would suggest that the project is economically justified because the overall gains to society outweigh the costs.
ORIGIN OF THE TERM
CBA originates in welfare economics and public policy evaluation, with early foundations in the work of Jules Dupuit (1844) on social utility and later formalisation by Kaldor and Hicks through the compensation principle.2 The modern regulatory and antitrust usage developed in the mid-twentieth century in the United States, particularly through public infrastructure appraisal and law-and-economics scholarship. In competition law, CBA entered doctrinally through efficiency defences and effects-based analysis in merger control and Article 101(3) TFEU3.
COMMENTARY
Cost–benefit analysis provides the conceptual basis for effects-based antitrust enforcement. Rather than condemning conduct solely on formalistic grounds, contemporary competition law increasingly asks whether a practice produces net welfare gains or losses. In merger control, CBA underlies the efficiency defence: even if a transaction increases market power, it may be cleared if merger-specific efficiencies are likely to be passed on to consumers and outweigh the competitive harm.
In the United States, the Horizontal Merger Guidelines rely on a balancing of anticompetitive effects and cognizable efficiencies.4 In FTC v HJ Heinz Co, the DC Circuit accepted that efficiencies could rebut a prima facie case of anticompetitive effects but stressed the high evidentiary burden where concentration and price effects are significant.5
In the European Union, Article 101(3) TFEU permits the exemption of restrictive agreements when efficiencies outweigh competitive harm, and consumers receive a fair share of the benefits. The Court of Justice in Intel confirmed that an effects-based assessment must weigh foreclosure against efficiencies.6 Under the SIEC test, the Commission in Dow/DuPont and Bayer/Monsanto examined whether claimed efficiencies and innovation synergies outweighed the loss of competitive R&D rivalry.7
In India, Section 19(3) of the Competition Act, 2002 embodies an implicit cost–benefit framework by requiring the balancing of anticompetitive effects with consumer benefits and efficiency gains. In Sun Pharmaceutical Industries Ltd/Ranbaxy Laboratories Ltd, the CCI imposed structural remedies where efficiencies were insufficient to offset likely price and innovation harms.8
At the policy level, the OECD and the International Competition Network emphasise CBA as a tool to avoid over-enforcement and ensure that intervention enhances overall welfare.9
European Commission, Guidelines on the Assessment of Horizontal Mergers (2004) OJ C31/5
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52004XC0205(02)↩︎Nicholas Kaldor, ‘Welfare Propositions of Economics and Interpersonal Comparisons of Utility’ (1939) 49 Economic Journal 549; John Hicks, ‘The Foundations of Welfare Economics’ (1939) 49 Economic Journal 696.↩︎
Consolidated Version of the Treaty on the Functioning of the European Union [2012] OJ C 326/88, art 101. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:12012E/TXT:en:PDF↩︎
US Department of Justice & Federal Trade Commission, Horizontal Merger Guidelines (2010; 2023)
https://www.justice.gov/atr/merger-guidelines↩︎FTC v HJ Heinz Co 246 F3d 708 (DC Cir 2001)
https://law.justia.com/cases/federal/appellate-courts/F3/246/708/↩︎Intel Corp v Commission (Case C-413/14 P) EU:C:2017:632
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:62014CJ0413↩︎Dow/DuPont (Case M.7932) Commission Decision (2017)
https://competition-cases.ec.europa.eu/cases/M.7932
Bayer/Monsanto (Case M.8084) Commission Decision (2018)
https://ec.europa.eu/competition/mergers/cases1/202150/M_8084_8063669_13738_3.pdf↩︎Sun Pharmaceutical Industries Ltd/Ranbaxy Laboratories Ltd (CCI Combination Registration No C-2014/05/170)
http://164.100.58.95/sites/default/files/C-2014-05-170A_0.pdf.↩︎OECD, Policy Roundtable on Efficiency Claims in Antitrust DAF/COMP(2012)
https://www.oecd.org/content/dam/oecd/en/publications/reports/2013/05/the-role-of-efficiency-claims-in-antitrust-proceedings_a1fda930/ceaed16d-en.pdf ; International Competition Network, Merger Guidelines Workbook (2021)
https://www.internationalcompetitionnetwork.org↩︎
